Internal Server Error

Immunis - About the company

Immunis is a series A company based in Irvine (United States), founded in 2018. It operates as a Developer of cell therapies for age-related and disease-related immune deficits. Immunis has raised $67.4M in funding from Remiges Ventures. The company has 151 active competitors, including 45 funded and 17 that have exited. Its top competitors include companies like Retro, Eupraxia Pharmaceuticals and TissueGene.

Company Details

Developer of cell therapies for age-related and disease-related immune deficits. It offers a STEM product line developed from human stem cells that secrete immune modulators for treating muscle atrophy in patients with knee osteoarthritis and muscle performance in seniors with obesity and muscle weakness.
Email ID
*****@immunisbiomedical.com
Key Metrics
Founded Year
2018
Location
Irvine, United States
Stage
Series A
Total Funding
$67.4M in 4 rounds
Latest Funding Round
Ranked
Employee Count
24 as on Sep 30, 2026
Similar Companies
Sign up to download Immunis' company profile

Immunis's funding and investors

Immunis has raised a total funding of $67.4M over 4 rounds. Its first funding round was on Aug 04, 2022. Immunis has 6 institutional investors.

Here is the list of recent funding rounds of Immunis:lockFilter this list
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
May 28, 2026
6842008
Series A
6085110
7206912
5516629
4296635
Jan 11, 2025
7368416
Series A
8247675
4683910
5753723
Jun 17, 2024
3450886
Series A
1978558
3710752
6058008
9089702
lockAccess funding benchmarks and valuations. Sign up today!

Immunis' founders and board of directors

Founder? Claim Profile

Immunis' employee count trend

Immunis has 24 employees as of Sep 26. Here is Immunis's employee count trend over the years:
Employee count trend for Immunis
lockUncover Immunis' growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Immunis's Competitors and alternates

Top competitors of Immunis include Retro, Eupraxia Pharmaceuticals and TissueGene. Here is the list of Top 10 competitors of Immunis, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Retro
Retro
2020, Redwood City (United States), Series D
Developer of therapeutics targeting cellular mechanisms to treat aging diseases
$180M
-
65/100
2nd
Logo for Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals
2012, Vancouver (Canada), Public
Sustained released formulation for osteoarthritis
$2.44M
62/100
3rd
Logo for TissueGene
TissueGene
1999, Rockville (United States), Series C
Developer of regenerative therapies for orthopedic diseases
$94.6M
58/100
4th
Logo for Remedium Bio
Remedium Bio
2020, Needham (United States), Series A
Developer of gene therapies for a broad range of diseases
$15M
57/100
5th
Logo for Levicept
Levicept
2012, Sandwich (United Kingdom), Series B
Developer of therapeutics for the treatment of chronic pain
$50.9M
56/100
6th
Logo for Immunis
Immunis
2018, Irvine (United States), Series A
Developer of cell therapies for age-related and disease-related immune deficits
$67.4M
56/100
7th
Logo for Ensoma
Ensoma
2019, Boston (United States), Series B
Developer of in vivo hematopoietic stem cell engineering for genomic medicine
$205M
54/100
8th
Logo for RenewalBio
RenewalBio
2022, Rehovot (Israel), Seed
Developer of a synthetic embryo and stem-cell therapeutic platform
-
52/100
9th
Logo for ZEO ScientifiX
ZEO ScientifiX
2011, Fort Lauderdale (United States), Seed
Biopharmaceutical company focused on researching novel biological therapeutics
$1M
-
52/100
10th
Logo for Athersys
Athersys
1995, Cleveland (United States), Public
Stem Cell Therapy for the treatment of cardiovascular disease areas
$74.4M
52/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Immunis's competitors? Click here to see the top ones

Immunis's Investments and acquisitions

Immunis has made no investments or acquisitions yet.

Reports related to Immunis

Here is the latest report on Immunis's sector:

News related to Immunis

lockFilter this list
Media has covered Immunis for a total of 3 events in the last 1 year, 2 of them have been about company updates.
•
Immunis to use MRI-based AI muscle analysis for sarcopenia trialhttps://www.clinicaltrialsarena.com/•Jul 26, 2024•Immunis
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about Immunis

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford